Noonan syndrome (NS) is an autosomal dominant disorder, with variable phenotypic expression, characterized by short stature, facial dysmorphisms and heart disease. Different genes of the RAS/MAPK signaling pathway are responsible for the syndrome, the most common are: PTPN11, SOS1, RAF1, and KRAS. The objective of this study was to report a patient with Noonan syndrome presenting mutations in two genes of RAS/MAPK pathway in order to establish whether these mutations lead to a more severe expression of the phenotype. We used direct sequencing of the PTPN11, SOS1, RAF1, and KRAS genes. We have identified two described mutations in heterozygosity: p.N308D and p.R552G in the genes PTPN11 and SOS1, respectively. The patient has typical clinical features similar to the ones with NS and mutation in only one gene, even those with the same mutation identified in this patient. A more severe or atypical phenotype was not observed, suggesting that these mutations do not exhibit an additive effect.

Download full-text PDF

Source
http://dx.doi.org/10.1590/s0004-27302010000800009DOI Listing

Publication Analysis

Top Keywords

ptpn11 sos1
16
noonan syndrome
12
genes ras/mapk
8
sos1 raf1
8
raf1 kras
8
mutations
5
co-occurring ptpn11
4
sos1
4
sos1 gene
4
gene mutations
4

Similar Publications

Unlabelled: The RASopathies are a group of disorders resulting from a germline variant in the genes encoding the Ras/mitogen-activated protein kinase pathway. These disorders include Noonan syndrome (NS), cardiofaciocutaneous syndrome (CFC), Costello syndrome (CS), Legius syndrome (LS), and neurofibromatosis type 1 (NF1), and have overlapping clinical features due to RAS/MAPK dysfunction. In this study, we aimed to describe the clinical and molecular features of patients exhibiting phenotypic manifestations consistent with RASopathies.

View Article and Find Full Text PDF

Noonan syndrome and related disorders are a group of well-known genetic conditions caused by dysregulation of the Ras/mitogen-activated protein kinase (RAS/MAPK) pathway. Because of the overlap of clinical and molecular features, they are now called RASopathies. In this study, we retrospectively analyzed the clinical data of 121 patients with a molecularly confirmed diagnosis of RASopathy, describing frequencies for clinical features in all organ systems as well as molecular data.

View Article and Find Full Text PDF
Article Synopsis
  • * Direct KRAS inhibitors are showing promise in clinical trials, but resistance to treatment is a concern, prompting the search for combination therapies.
  • * Unbiased drug screening identified effective combinations involving SOS1 inhibitors, PTPN11/SHP2 inhibitors, and multi-kinase inhibitors, validated using a unique KRAS-mutated patient-derived organoid model.
View Article and Find Full Text PDF

Introduction: Growth patterns in Noonan syndrome (NS) remain relatively unknown. The objective of this study was to provide growth reference curves for patients with NS and identify correlations between their growth, genotype, and clinical features.

Methods: This was a 15-year-long, monocentric, observational, retrospective, non-interventional study.

View Article and Find Full Text PDF
Article Synopsis
  • * The discussion includes the polygenic causes of calcific aortic valve disease, focusing on the importance of NOTCH1 mutations and the traits associated with bicuspid aortic valve disease.
  • * Aortic arch abnormalities, like coarctation and interrupted aortic arch, are linked to syndromes like Turner and 22q11 deletion, along with genetic factors contributing to congenital pulmonary valve stenosis and related syndromes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!